Zafirlukast-13C,d6

Zafirlukast-13C,d6

• UNSPSC Description: Zafirlukast-13C,d6 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
• Target Antigen: Isotope-Labeled Compounds; Leukotriene Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Others
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Cancer
• Solubility: 10 mM in DMSO
• Smiles: O=C(NC1=CC(C(CC2=CC=C(C(NS(=O)(C3=C(C)C=CC=C3)=O)=O)C=C2O[13C]([2H])([2H])[2H])=CN4C([2H])([2H])[2H])=C4C=C1)OC5CCCC5
• Molecular Weight: 582.70
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D₄ receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746-9.|[3]Gunning WT, et al. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.|[4]Lei C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68-73.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported